Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.

Autor: Ferreri CJ; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hildebrandt MAT; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hashmi H; Medical University of South Carolina, Charleston, SC, USA., Shune LO; The University of Kansas Medical Center, Kansas City, KS, USA., McGuirk JP; The University of Kansas Medical Center, Kansas City, KS, USA., Sborov DW; The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA., Wagner CB; The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA., Kocoglu MH; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Rapoport A; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA., Atrash S; Levine Cancer Institute, Charlotte, NC, USA., Voorhees PM; Levine Cancer Institute, Charlotte, NC, USA., Khouri J; Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA., Dima D; Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA., Afrough A; Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Kaur G; Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Anderson LD Jr; Myeloma, Waldenstrom's, and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA., Simmons G; Virginia Commonwealth University Massey Cancer Center, Richmond, VA, USA., Davis JA; Medical University of South Carolina, Charleston, SC, USA., Kalariya N; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Peres LC; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Lin Y; Mayo Clinic, Rochester, MN, USA., Janakiram M; City of Hope, Duarte, CA, USA., Nadeem O; Dana-Farber Cancer Institute, Boston, MA, USA., Alsina M; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Locke FL; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Sidana S; Stanford University School of Medicine, Stanford, CA, USA., Hansen DK; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Patel KK; The University of Texas MD Anderson Cancer Center, Houston, TX, USA. KPatel1@mdanderson.org., Castaneda Puglianini OA; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
Jazyk: angličtina
Zdroj: Blood cancer journal [Blood Cancer J] 2023 Aug 09; Vol. 13 (1), pp. 117. Date of Electronic Publication: 2023 Aug 09.
DOI: 10.1038/s41408-023-00886-8
Abstrakt: Most patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers. A total of 50 patients with prior BCMA-TT exposure (38 antibody-drug conjugate, 7 bispecific, 5 CAR T) and 153 patients with no prior BCMA-TT were infused with ide-cel, with a median follow-up duration of 4.5 and 6.0 months, respectively. Safety outcomes between cohorts were comparable. The prior BCMA-TT cohort had a lower overall response rate (74% versus 88%; p = 0.021), median duration of response (7.4 versus 9.6 months; p = 0.03), and median progression-free survival (3.2 months versus 9.0 months; p = 0.0002) compared to the cohort without prior BCMA-TT. All five patients who received a prior anti-BCMA CAR T responded to ide-cel, and survival outcomes were best for this subgroup. In conclusion, treatment with ide-cel yielded meaningful clinical responses in real-world patients exposed to a prior BCMA-TT, though response rates and durability were suboptimal compared to those not treated with a prior BCMA-TT.
(© 2023. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: